Press Release: LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

Dow Jones12-19 22:05
Total operating expenses               404,164      276,404       39,445 
                                    ----------  -----------  ----------- 
 
Income (loss) from operations        (183,259)       30,858        4,404 
 
Other income (expenses): 
 Late fees related to social 
  security insurance                     (446)        (213)         (30) 
 Government grants                      14,628        3,864          551 
 Financial expenses - net             (12,968)      (6,573)        (938) 
 Fair value changes of warrant 
  liability                              6,851          315           45 
 Other income (expense) - net            (149)      (6,454)        (921) 
Total other income (expense) - net       7,916      (9,061)      (1,293) 
                                    ----------  -----------  ----------- 
 
Income (loss) before income taxes    (175,343)       21,797        3,111 
Income tax benefit (expense)               820      (1,218)        (174) 
                                    ----------  -----------  ----------- 
 
Net income (loss)                    (174,523)       20,579        2,937 
                                    ----------  -----------  ----------- 
 
Net income (loss) attributable to 
 Lakeshore Group                     (174,523)       20,579        2,937 
                                    ==========  ===========  =========== 
 
Net income (loss)                    (174,523)       20,579        2,937 
 Other comprehensive income 
  (loss): Foreign currency 
  translation adjustment                 3,166      (4,900)        (700) 
                                    ----------  -----------  ----------- 
Total comprehensive income (loss)    (171,357)       15,679        2,237 
                                    ==========  ===========  =========== 
 
Earnings (loss) per share: 
 -- Basic and Diluted                   (1.88)         0.11         0.02 
                                    ==========  ===========  =========== 
Weighted average number of 
ordinary shares outstanding: 
 -- Basic and Diluted               93,058,197  190,429,732  190,429,732 
                                    ==========  ===========  =========== 
 
 
                      Lakeshore Biopharma Co., Ltd 
             Unaudited Reconciliations of Non-GAAP Results 
                       (All amounts in thousands) 
 
                                     Six Months Ended September 30, 
                                     ----------------------------------- 
                                          2023          2024      2024 
                                      -------------  ----------  ------- 
                                           RMB          RMB        US$ 
 
Net income (loss)                         (174,523)      20,579    2,937 
Add: income tax expense (benefit)             (820)       1,218      174 
Add: financial expenses - net                12,968       6,573      938 
Add: depreciation and amortization           23,734      25,414    3,627 
                                      -------------  ----------  ------- 
EBITDA                                    (138,641)      53,784    7,676 
                                      =============  ==========  ======= 
 
Add: Share-based compensation 
 expenses                                         -       1,659      237 
Add: late fees related to social 
 security insurance                             446         213       30 
Add: other income (expense) - net               149       6,454      921 
Add: fair value changes of warrant 
 liability                                  (6,851)       (315)     (45) 
Add: government grants                     (14,628)     (3,864)    (551) 
                                      -------------  ----------  ------- 
Adjusted EBITDA                           (159,525)      57,931    8,268 
                                      =============  ==========  ======= 
 
                                     Six Months Ended September 30, 
                                     ----------------------------------- 
                                          2023          2024      2024 
                                      -------------  ----------  ------- 
                                           RMB          RMB        US$ 
 
Net income (loss)                         (174,523)      20,579    2,937 
Add: share-based compensation 
 expenses                                         -       1,659      237 
Add: loss on disposal of property, 
 plant and equipment                              -       8,210    1,172 
                                      -------------  ----------  ------- 
Adjusted net income (loss)                (174,523)      30,448    4,346 
                                      =============  ==========  ======= 
 

View original content:https://www.prnewswire.com/news-releases/lakeshore-biopharma-reports-unaudited-financial-results-for-the-first-half-of-fiscal-year-2025-and-updates-full-year-guidance-302336215.html

SOURCE LakeShore Biopharma

/CONTACT: Yiyang Wang, ir@lakeshorebio.com

 

(END) Dow Jones Newswires

December 19, 2024 09:05 ET (14:05 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment